5 patents currently held
24 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jul 2030. from the record
Of the 24 now held by other companies, 10 were conveyed to Syzygymed Inc. in the filing they arrived in, and 14 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Jul 2030
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends no later than Aug 2039 · Medium confidence
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
conveyed to Vor Biopharma Inc. - now held by Syzygymed Inc.
Also notable
Ends Jun 2028 · High confidence
The most cited patent in this portfolio, cited by 71 later US patents, top 10% of utility patents granted in 2013 in our data. Protection runs to 2028.
now held by Celea Therapeutics, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 6, 2027
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,238,643 | Methods and Compositions for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation In force · High confidence | In force | High confidence | |
| US 10,265,311 | Methods and Compositions for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation In force · Medium confidence | In force | Medium confidence | |
| US 10,369,143 | Methods and Compositions for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation In force · High confidence | In force | High confidence | |
| US 10,369,144 | Methods and Compositions for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation In force · High confidence | In force | High confidence | |
| US 10,695,339 | Methods and Compositions for Treatment of Disorders Ameliorated by Muscarinic Receptor Activation In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 24 patents in force now held by others · 7 applications pending · 10 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
7 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.